Additional information, including the accepted abstracts, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available in the Science section under Scientific ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...

With its wealth of experience, Creative Biolabs stands ready to support global researchers in advancing their iPSC-derived cell therapy studies. SHIRLEY, NY, UNITED STATES, May 20, 2025 /EINPresswire.

GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for ...

Combined with Pluristyx’s best-in-class mRNA reprogramming method, the result is a universal, clinical-grade iPSC line. “This addition to our patent portfolio further enables our commitment to ...

Unlike other commercially available iPSC lines, PluriBank™ iPSCs are ... footprint-free RNA reprogramming method, ensuring high reprogramming efficiency, genomic integrity, low passage number ...

“Our deep expertise in iPSC reprogramming, gene editing, and differentiation, combined with this expanded manufacturing capability, makes Cellistic a trusted partner for innovators looking to bring ...